Boudes Pol F 4
4 · GALECTIN THERAPEUTICS INC · Filed Jan 25, 2022
Insider Transaction Report
Form 4
Boudes Pol F
Chief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2022-01-24+50,000→ 50,000 totalExercise: $1.98Exp: 2032-01-24→ Common Stock (50,000 underlying)
Footnotes (2)
- [F1]The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan.
- [F2]The options vest as follows: 25% on each of June 30, 2022; December 31, 2022; June 30, 2023; and December 31, 2023.